SYK STRYKER CORPORATION

Stryker announces Allan Golston will retire from Board of Directors

Stryker announces Allan Golston will retire from Board of Directors

Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025.

 

Golston joined Stryker’s Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees.



“We are grateful for Allan’s many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We thank Allan for his leadership and dedication in helping Stryker advance our mission of making healthcare better.”



Golston has served as the President, United States Program for the Bill & Melinda Gates Foundation since 2006, and as Chief Financial and Administrative Officer of the Bill & Melinda Gates Foundation from 2000 to 2006. He is also a director of Harley-Davidson, Inc., a manufacturer of motorcycles and accessories. Golston has extensive experience in auditing, finance and the healthcare industry. He is a certified public accountant and has held hospital finance executive positions. In his service to the Gates Foundation, he has contributed to the strategic formation and operation of successful initiatives to provide healthcare, education and other human needs, all of which gave him an understanding that assisted Stryker in its global efforts to meet the needs of patients and caregivers.



About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at .

Contacts

For investor inquiries please contact:

Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or  

For media inquiries please contact:

Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or



EN
10/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

 PRESS RELEASE

Stryker to announce financial results for its first quarter of fiscal ...

Stryker to announce financial results for its first quarter of fiscal year 2025 Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results.  ...

 PRESS RELEASE

Stryker completes sale of U.S. spinal implants business

Stryker completes sale of U.S. spinal implants business Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. “The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth,” said Kevin Lobo, Chair and CEO, Stryker. “We remain...

 PRESS RELEASE

Stryker announces intention to nominate Manny Maceda to board of direc...

Stryker announces intention to nominate Manny Maceda to board of directors Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and...

 PRESS RELEASE

Stryker announces Annual Meeting of Shareholders

Stryker announces Annual Meeting of Shareholders Portage, Michigan, March 25, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2025 Annual Meeting of Shareholders is scheduled as follows: Thursday, May 8, 2025 – 9:30 a.m. Eastern Time The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at . To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker...

 PRESS RELEASE

Stryker completes acquisition of Inari Medical, Inc., providing entry ...

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. “The acquisition of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch